Clinical trials: sponsored by Amgen
Osteogenesis Imperfecta (OI)
Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta
To evaluate long-term safety of denosumab in children/young adults with pediatric osteogenesis imperfecta (OI) who completed the prior study 20130173 (NCT02352753).
- Trial name
- NCT03638128
- Testing
- Denosumab, Alternative osteoporosis medications
- Where
- 22 sites in United States, Australia and 10 more
- Volunteers
- 75 people
- Sponsor
- Amgen
Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia
Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
This is an open-label, combined 2-part multicenter study to evaluate the efficacy, safety, and tolerability of blinatumomab in adult and pediatric Japanese patients with relapsed/refractory B-precursor ALL.
- Trial name
- NCT02412306
- Testing
- Blinatumomab
- Where
- 16 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Amgen
Multiple Myeloma
Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe
With the recent addition of carfilzomib as a treatment option for multiple myeloma, no data is available yet on how the drug is being used outside of the clinical trial setting.
- Trial name
- NCT03091127
- Where
- 114 sites in Austria, Belgium and 9 more
- Volunteers
- 705 people
- Sponsor
- Amgen
Colon Cancer, Colorectal Cancer
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
The primary objective of this study is to estimate the treatment effect on progression-free survival (PFS) of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in patients with…
- Conditions
- Colon Cancer, Colorectal Cancer, Rectal Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT00819780
- Testing
- Panitumumab, Bevacizumab, mFOLFOX6
- Where
- 95 sites in United States, Belgium and 4 more
- Volunteers
- 285 people
- Sponsor
- Amgen
Primary Hypercholesterolemia, Mixed Dyslipidemia
Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in a home-use setting using either an automated mini-doser (AMD) or autoinjector/pen (AI/pen).
- Trial name
- NCT01879319
- Testing
- Evolocumab AMD, Evolocumab AI/pen
- Where
- 27 sites in United States, Canada
- Volunteers
- 164 people
- Sponsor
- Amgen
Hypercholesterolemia
Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment
To evaluate the efficacy of subcutaneous (SC) evolocumab, compared to regularly scheduled low-density lipoprotein cholesterol (LDL-C) apheresis, on reducing the need for future apheresis.
- Trial name
- NCT02585895
- Testing
- Evolocumab, Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
- Where
- 17 sites in United States, Australia and 6 more
- Volunteers
- 39 people
- Sponsor
- Amgen
Non-Small Cell Lung Cancer, Anemia
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
This is a study in patients with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC).
- Conditions
- Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
- Trial name
- NCT00858364
- Testing
- Darbepoetin alfa
- Where
- 566 sites in United States, Argentina and 35 more
- Volunteers
- 2,549 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
The primary objective of the study was to evaluate the effect of 12 months of treatment with romosozumab compared with teriparatide on total hip bone mineral density (BMD) in postmenopausal women with osteoporosis who were…
- Trial name
- STRUCTURE (NCT01796301)
- Testing
- Romozosumab, Teriparatide
- Where
- 50 sites in United States, Argentina and 9 more
- Volunteers
- 436 people
- Sponsor
- Amgen
Osteoporosis, Age-Related
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
The objective of this study was to describe persistence with Prolia® 60 mg administered subcutaneously (SC) every 6 months (Q6M) at 12 and 24 months.
- Trial name
- NCT02732210
- Where
- 89 sites in United States, Canada
- Volunteers
- 935 people
- Sponsor
- Amgen
Anemia, Chronic Kidney Disease
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
The primary objectives of this study are the following: 1. To test if the proportion of participants achieving a hemoglobin value greater than or equal to 10.0 g/dL at any time point after the first dose during the study is…
- Conditions
- Anemia, Chronic Kidney Disease, Kidney Disease
- Trial name
- NCT00436748
- Testing
- Darbepoetin Alfa
- Where
- 67 sites in United States, Belgium and 8 more
- Volunteers
- 116 people
- Sponsor
- Amgen
Breast Cancer
Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
The purpose of this study is to determine if patient education can affect patient reported bone pain in breast cancer patients receiving chemotherapy and pegfilgrastim.
- Trial name
- VINE (NCT01752907)
- Testing
- General Education DVD, Bone Pain Education DVD
- Where
- 51 sites in United States
- Volunteers
- 304 people
- Sponsor
- Amgen
Hyperlipidemia
LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy
To evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab (AMG 145) administered every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on percent change from baseline in LDL-C when used in addition to a…
- Trial name
- LAPLACE (NCT01380730)
- Testing
- Evolocumab
- Where
- 100 sites in United States, Canada and 3 more
- Volunteers
- 631 people
- Sponsor
- Amgen
Hypercholesterolemia, Familial
Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with placebo, on percent change from baseline in LDL-C in adults with heterozygous familial…
- Trial name
- RUTHERFORD (NCT01375751)
- Testing
- Evolocumab
- Volunteers
- 168 people
- Sponsor
- Amgen
Multiple Myeloma
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.
- Trial name
- ENDEAVOR (NCT01568866)
- Testing
- Carfilzomib, Bortezomib, Dexamethasone
- Where
- 241 sites in United States, Australia and 25 more
- Volunteers
- 929 people
- Sponsor
- Amgen
Post Menopausal Osteoporosis
Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France
The purpose of the study is to describe the characteristics and management of post menopausal women with osteoporosis treated with Prolia in France, and examine the use of Prolia in routine clinical practice in France
- Trial name
- PILOTE (NCT02347865)
- Testing
- AMG 162 - Prolia
- Where
- France
- Volunteers
- 777 people
- Sponsor
- Amgen
Multiple Myeloma
Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma
The primary objectives of this study included the following: Phase 1b: To establish the maximum tolerated dose (MTD) of oprozomib given in combination with lenalidomide and dexamethasone (ORd) or with cyclophosphamide and…
- Trial name
- NCT01881789
- Testing
- Oprozomib, Lenalidomide, Dexamethasone
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amgen
Idiopathic Thrombocytopenic Purpura, Thrombocytopenia
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
This protocol will provide open label romiplostim to adult thrombocytopenic subjects. Romiplostim will be administered by subcutaneous injection once per week.
- Conditions
- Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenic Purpura
- Trial name
- NCT00508820
- Testing
- Romiplostim
- Volunteers
- 407 people
- Sponsor
- Amgen
Melanoma
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
The primary objectives of the Phase 1b part of the study are to evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab in adults with…
- Trial name
- MASTERKEY-265 (NCT02263508)
- Testing
- Talimogene Laherparepvec, Pembrolizumab
- Where
- 161 sites in United States, Australia and 19 more
- Volunteers
- 713 people
- Sponsor
- Amgen
Kidney Disease, Diabetes Mellitus
Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)
The purpose of this study is to assess the impact of treatment of anemia with darbepoetin alfa to a hemoglobin target of 13 g/dL on (1) all-cause mortality and nonfatal cardiovascular events, and (2) progression to end-stage…
- Conditions
- Kidney Disease, Diabetes Mellitus, Anemia
- Trial name
- NCT00093015
- Testing
- darbepoetin alfa
- Volunteers
- 4,038 people
- Sponsor
- Amgen
Advanced Malignancy, Advanced Solid Tumors
Safety Study of AMG 228 to Treat Solid Tumors
The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology
- Trial name
- NCT02437916
- Testing
- AMG 228
- Where
- 7 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.